Edward V. Nunes, MD

Expertise in: 
General Psychiatry / Psychology, Depression, Anxiety Disorders
Board Certifications: 
Addiction Psychiatry, Psychiatry
Accepting New Patients

Overview

Areas of Expertise / Conditions Treated

General Psychiatry / Psychology, Depression, Anxiety Disorders, Alcoholism, Substance Use, Depression, Alcohol Use Disorders, Opioid Use Disorders

Academic Appointments

  • Professor of Psychiatry at CUMC

Dr. Nunes is a Professor of Psychiatry at Columbia University Irving Medical Center and Research Psychiatrist at New York State Psychiatric Institute. He is an internationally recognized leader in research on treatments for opioid use disorder and other substance use disorders, and on co-occurring psychiatric and substance use disorders. For the past thirty years with continuous funding from NIH, mainly National Institute on Drug Abuse (NIDA), including a series of Career Development Awards, he has led clinical trials on medication and behavioral treatments for cocaine and opioid use disorders. He has over 250 peer-reviewed scientific publications, including papers in JAMA, New England Journal of Medicine, and Lancet, in addition to numerous book chapters and a textbook on diagnosis and treatment of co-occurring psychiatric disorders among patients with substance use disorders. His group was among the first to demonstrate that depression could be identified with careful clinical diagnosis and successfully treated among patients with alcohol, opioid or cocaine use disorders, and to demonstrate that behavioral intervention could improve the effectiveness of naltrexone as a treatment for opioid use disorder.

For the past 20 years he has served as a Principal Investigator in the NIDA Clinical Trials Network (CTN, New York Node), focused on clinical trials to demonstrate the effectiveness of new treatments in real-world clinical settings. Among other accomplishments his group led the first large multisite trial of behavioral treatment for post-traumatic stress disorder among women with substance use disorders, the first large multi-site trial of a technology-delivered behavioral treatment for substance use disorders, and co-led the first large U.S.-based trial comparing extended-release injection naltrexone versus sublingual buprenorphine for treatment of opioid use disorder. Currently in the CTN, he and his colleagues are developing a major clinical trial that will be a cornerstone of the NIH HEAL Initiative (Help End Addiction in our Lifetimes), testing strategies--different medication doses and formulations, and behavioral treatments--to improve the effectiveness of buprenorphine and injection naltrexone for treatment of opioid use disorder. He is also a multiple Principal Investigator on the New York Healing Communities Study, a major NIH funded effort which, along with 3 other States, seeks to demonstrate that a concerted community wide effort to expand medication treatment and other interventions can drive down the high rate of deaths from opioid overdose.

He has served on the Board of Directors of the College on Problems of Drug Dependence, the American Board of Addiction Medicine and the Addiction Medicine Foundation, and National Advisory Council on Drug Abuse, and currently serves on the NIH Working Group on the HEAL Initiative, the Addiction Medicine sub-Board of the American Board of Preventive Medicine, and is Deputy Editor of the American Journal of Drug and Alcohol Abuse. Locally, he has been active throughout his career mentoring research fellows and junior faculty, and he serves as Co-Chair of the New York State Psychiatric Institute/Columbia University Department of Psychiatry Institutional Review Board.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Credentials & Experience

Education & Training

  • University of Connecticut School of Medicine
  • Internship: St. Elizabeth's Medical Center, Boston
  • Residency: Columbia Presbyterian Medical Center, NY
  • Fellowship: New York State Psychiatric Institute

Board Certifications

  • Addiction Psychiatry
  • Psychiatry
America's Top Doctor
NY Top Doctor

Research

Grants

FACILITATING OPIOID CARE CONNECTIONS: SYSTEM LEVEL STRATEGIES TO IMPROVE USE OF MAT AND MOVEMENT THROUGH THE OPIOID CARE CASCADE FOR DEFENDANTS IN A NEW OPIOID COURT SYSTEM (Federal Gov)

Jul 15 2019 - Apr 30 2024

EVALUATION OF SAFETY AND PHARMACOKINETICS OF NALTREXONE IMPLANT (Federal Gov)

Sep 15 2018 - Aug 31 2023

COORDINATED MEDICAL TREATMENT OF OPIOID USE DISORDER AND INFECTIOUS DISEASE (Federal Gov)

Jul 18 2019 - Jun 30 2023

INVESTIGATION OF THE NMDA ANTAGONIST KETAMINE AS A TREATMENT FOR TINNITUS (Federal Gov)

Jan 1 2019 - Jun 14 2022

COMPREHENSIVE CBT VIA RESET FOR A HUB AND SPOKE MAT SYSTEM OF CARE (Federal Gov)

Sep 20 2018 - Sep 19 2021

MISSING DATA MATTERS: SUBSTANCE USE DISORDER CLINICAL TRIALS (Federal Gov)

Aug 15 2018 - Apr 30 2021

FY 2018 OPIOID STATE TARGETED RESPONSE TECHNICAL ASSISTANCE (STR TA) (Federal Gov)

Feb 1 2018 - Jan 31 2021

PHASE 1A/1B CLINICAL TRIALS OF MULTIVALENT OPIOID VACCINE (Federal Gov)

Sep 1 2019 - Aug 31 2020

RISK AND BENEFITS OF OVERDOSE EDUCATION AND NALOXONE PRESCRIBING TO HEROIN USERS (Federal Gov)

Sep 15 2014 - Aug 31 2020

INDIVIDUAL LEVEL PREDICTIVE MODELING OF OPIOID USE DISORDER TREATMENT RESPONSE USING AGGREGATE CTN DATASETS (Federal Gov)

Jun 1 2019 - May 31 2020

CLINICAL TRIALS NETWORK: GREATER NEW YORK NODE (CTN-0097: SWIFT (NALTREXONE INDUCTION) (Federal Gov)

Mar 29 2019 - May 31 2020

FY 2018 OPIOID STATE TARGETED RESPONSE TECHNICAL ASSISTANCE (STR TA) (Federal Gov)

Feb 1 2018 - Apr 30 2020

FY 2018 OPIOID STATE TARGETED RESPONSE TECHNICAL ASSISTANCE (STR TA) (Federal Gov)

Feb 1 2018 - Jan 31 2020

FY 2018 OPIOID STATE TARGETED RESPONSE TECHNICAL ASSISTANCE (STR TA) (Federal Gov)

Feb 1 2018 - Jan 31 2020

TRAINING MEDICAL AND DENTAL STUDENTS IN SBIRT (Federal Gov)

Sep 30 2015 - Sep 29 2019

PROVIDERS CLINICAL SUPPORT SYSTEM FOR MEDICATION ASSISTED TREATMENT (PCSS-MAT) - TRAINING AND IMPLEMENTATION (Federal Gov)

Aug 1 2016 - Jul 31 2019

RISK AND BENEFITS OF OVERDOSE EDUCATION AND NALOXONE PRESCRIBING TO HEROIN USERS (Federal Gov)

Sep 15 2014 - Aug 31 2018

CLINICAL TRIALS NETWORK: GREATER NEW YORK NODE (CTN-0051) (Federal Gov)

Jun 1 2017 - May 31 2018

CLINICAL TRIALS NETWORK: GREATER NEW YORK NODE (CTN-0068) (Federal Gov)

Jun 1 2017 - May 31 2018

DRUG ABUSE TREATMENT DEVELOPMENT AND RESEARCH MENTORING (Federal Gov)

May 1 2007 - Apr 30 2018

RISK AND BENEFITS OF OVERDOSE EDUCATION AND NALOXONE PRESCRIBING TO HEROIN USERS (Federal Gov)

Sep 15 2014 - Feb 28 2018

A GAME-BASED INTERVENTION FOR OPIOID USE DISORDER (Private)

Jul 1 2017 - Dec 31 2017

RISK AND BENEFITS OF OVERDOSE EDUCATION AND NALOXONE PRESCRIBING TO HEROIN USERS (Federal Gov)

Sep 15 2014 - Aug 31 2017

SHARED PHARMACOTHERAPEUTIC STRATEGIES FOR CANNABINOID & OPIOID USE DISORDERS (Federal Gov)

Sep 1 2014 - Jun 30 2017

RISK AND BENEFITS OF OVERDOSE EDUCATION AND NALOXONE PRESCRIBING TO HEROIN USERS (Federal Gov)

Sep 15 2014 - Aug 31 2016